AHCYL1: A Potential Drug Target and Biomarker for Hyperlipidemia

Target Name: AHCYL1

NCBI ID: G10768

AHCYL1

AHCYL1: A Potential Drug Target and Biomarker for Hyperlipidemia

Abstract:

Hyperlipidemia, or excessive lipid levels, is a growing health concern due to its association with various cardiovascular diseases. The AHCYL1 gene, located on chromosome 14, has been identified as a potential drug target and biomarker for hyperlipidemia. This gene encodes the adenosine cytidease, 2 (AdoHcyase 2), which is involved in the breakdown of fatty acids and lipids. The current understanding of the role of AdoHcyase 2 in hyperlipidemia and its potential as a drug target is discussed in this article.

Introduction:

Hyperlipidemia is a condition characterized by an abnormal amount of lipids in the blood. It is a risk factor for various cardiovascular diseases, including heart disease, stroke, and diabetes. The number of people with hyperlipidemia worldwide has increased significantly in recent years due to factors such as an unhealthy diet, obesity, and decreased physical activity.

AHCYL1: A Potential Drug Target

The AHCYL1 gene has been identified as a potential drug target for hyperlipidemia due to its involvement in the breakdown of fatty acids and lipids. The AdoHcyase 2 gene encodes a protein that is involved in the metabolism of fatty acids and lipids. This protein is expressed in various tissues and cells in the body, including adipose tissue, muscle, and heart.

AdoHcyase 2 is a critical enzyme in the breakdown of fatty acids and lipids, which is essential for maintaining cellular energy homeostasis and maintaining the integrity of cell membranes. It is known to be involved in the production of ceramide, a type of dietary fat that can aid in the absorption of dietary cholesterol. In addition, AdoHcyase 2 is involved in the metabolism of triacylglycerols, which are a common type of dietary fat found in animal-based foods and are associated with an increased risk of hyperlipidemia.

AdoHcyase 2 has also been shown to be involved in the regulation of lipid metabolism in various organisms, including humans. Studies have shown that AdoHcyase 2 is involved in the metabolism of lipids in the liver, where it is known to play a role in the production of bile acids, which are essential for the digestion of fat.

A potential drug target for hyperlipidemia could be AdoHcyase 2 because of its involvement in the breakdown of fatty acids and lipids, which is a key step in the metabolism of dietary fat. Drugs that target AdoHcyase 2 have the potential to reduce the production of dietary fat and improve lipid profiles in individuals with hyperlipidemia.

Bioavailability and Interaction with Other Genes

AHCYL1 has also been shown to interact with other genes involved in lipid metabolism. One of these genes is the APOLIPOPROCARIOL (APOLIPOPROCARIOL) gene, which encodes a protein involved in the production of cholesterol. The APOLIPOPROCARIOL gene has been shown to interact with AHCYL1 to regulate the production of dietary fat in the liver.

Another gene that has been shown to interact with AHCYL1 is the uncoupling protein (UNC) gene, which encodes a protein involved in the metabolism of fatty acids and lipids. The UNC gene has been shown to interact with AHCYL1 to regulate the production of fatty acids from adipose tissue in the liver.

Molecular Mechanisms of Hyperlipidemia

The development of hyperlipidemia is a complex process that involves multiple genetic and environmental factors. It is characterized by an abnormal amount of lipids in the blood, including an increased number of low-density lipoprotein (LDL) cholesterol.

Aldolase, a enzyme involved in the breakdown of fatty acids and lipids, is a key gene that has

Protein Name: Adenosylhomocysteinase Like 1

Functions: Multifaceted cellular regulator which coordinates several essential cellular functions including regulation of epithelial HCO3(-) and fluid secretion, mRNA processing and DNA replication. Regulates ITPR1 sensitivity to inositol 1,4,5-trisphosphate, competing for the common binding site and acting as endogenous 'pseudoligand' whose inhibitory activity can be modulated by its phosphorylation status. Promotes the formation of contact points between the endoplasmic reticulum (ER) and mitochondria, facilitating transfer of Ca(2+) from the ER to mitochondria (PubMed:27995898). Under normal cellular conditions, functions cooperatively with BCL2L10 to limit ITPR1-mediated Ca(2+) release but, under apoptotic stress conditions, dephosphorylated which promotes dissociation of both AHCYL1 and BCL2L10 from mitochondria-associated endoplasmic reticulum membranes, inhibits BCL2L10 interaction with ITPR1 and leads to increased Ca(2+) transfer to mitochondria which promotes apoptosis (PubMed:27995898). In the pancreatic and salivary ducts, at resting state, attenuates inositol 1,4,5-trisphosphate-induced calcium release by interacting with ITPR1 (PubMed:16793548). When extracellular stimuli induce ITPR1 phosphorylation or inositol 1,4,5-trisphosphate production, dissociates from ITPR1 to interact with CFTR and SLC26A6, mediating their synergistic activation by calcium and cAMP that stimulates the epithelial secretion of electrolytes and fluid (By similarity). Also activates basolateral SLC4A4 isoform 1 to coordinate fluid and HCO3(-) secretion (PubMed:16769890). Inhibits the effect of STK39 on SLC4A4 and CFTR by recruiting PP1 phosphatase which activates SLC4A4, SLC26A6 and CFTR through dephosphorylation (By similarity). Mediates the induction of SLC9A3 surface expression produced by Angiotensin-2 (PubMed:20584908). Depending on the cell type, activates SLC9A3 in response to calcium or reverses SLC9A3R2-dependent calcium inhibition (PubMed:18829453). May modulate the polyadenylation state of specific mRNAs, both by controlling the subcellular location of FIP1L1 and by inhibiting PAPOLA activity, in response to a stimulus that alters its phosphorylation state (PubMed:19224921). Acts as a (dATP)-dependent inhibitor of ribonucleotide reductase large subunit RRM1, controlling the endogenous dNTP pool and ensuring normal cell cycle progression (PubMed:25237103). In vitro does not exhibit any S-adenosyl-L-homocysteine hydrolase activity (By similarity)

The "AHCYL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AHCYL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets